Vikram Thermo Share Price Target 2026, 2027, 2028, 2029, 2030

Vikram Thermo share price today

Vikram Thermo (India) (BSE: 530477) makes the coating that decides where a tablet dissolves. Its DRUGCOAT methacrylic-acid polymers and ready-to-use DRCOAT blends are applied to oral solid dosage forms so the drug survives stomach acid and releases in the intestine, or releases slowly over hours. It is a tiny company doing one unglamorous job inside somebody else’s medicine.

At the 6 August 2026 cut-off the share closed at ₹250.05, for a reconciled market capitalisation near ₹784 crore on trailing EPS of ₹12.27. The live quote above will drift from that; the analysis below stays pinned to the fixed date.

What makes this interesting is a contradiction inside the numbers. The operating margin is above 40% and the return on capital employed above 36%, which is chemical-franchise territory. Yet revenue grew only about 5% in FY26 and has compounded at roughly 12.75% over five years. The company is extremely profitable and not, on the recent record, fast-growing. The share sits within 3% of its 52-week high while that question is unresolved.

An excipient business, which is not a pharma business

It is easy to file this under pharmaceuticals and reach for the wrong mental model. Vikram Thermo sells no drug, owns no molecule, runs no clinical trial and faces no patent cliff. It sells a functional ingredient to formulators, and it competes with global excipient houses whose enteric polymers are the reference standard in most dossiers.

Layer of the business	What Vikram Thermo actually does	Consequence
Product	Methacrylic-acid based enteric and modified-release polymers	Functional, specified ingredient rather than a commodity filler
Format	DRUGCOAT base polymer and DRCOAT ready-to-use blends	Blends save the customer a formulation step and carry more value
Customer	Oral solid dosage formulators in India and export markets	Sticky once written into a filed dossier
Competitive set	Established global excipient suppliers	Vikram is the import-substitution alternative, not the standard
Switching cost	Regulatory filings name the coating system	Changing supplier can mean re-filing, which buys real retention

That last row is the whole moat. When a formulator files a product, the coating system is part of the specification. Replacing it is a regulatory exercise, not a purchasing decision. This is why a company with modest revenue can hold a 40% operating margin — and equally why winning a new customer is slow, because the opportunity only arises when a new dossier is being written.

FY26: profit grew three times faster than sales

The audited year to March 2026 showed total income of about ₹135.72 crore against roughly ₹129.14 crore a year earlier, an increase near 5%. Net profit rose about 14% to roughly ₹38.50 crore from about ₹33.76 crore.

FY26 measure	FY25	FY26	Change
Total income	About ₹129.14 Cr	About ₹135.72 Cr	Up about 5%
Net profit	About ₹33.76 Cr	About ₹38.50 Cr	Up about 14%
Implied net margin	About 26%	About 28%	Widened
Final dividend	—	₹1.25 per share	Declared on ₹10 face value

The March quarter carried much of it. Q4 FY26 total income rose to roughly ₹38.70 crore from about ₹28.14 crore, and net profit more than doubled to about ₹8.52 crore from roughly ₹4.07 crore. A single strong quarter in a company this small can reflect order timing as easily as a step-change in demand, so we would not annualise it.

The June 2026 quarter, reported after our cut-off and therefore outside the valuation base, showed sales of about ₹38 crore with net profit near ₹13 crore. That is the same pattern again, and more extreme: annualising the sales line gives roughly 12% growth on FY26, while annualising profit gives something closer to 35%. The margin is still doing the work.

The growth question, stated honestly

A 28% net margin on ₹136 crore of income is a good business. Whether it is a good investment at 20 times earnings depends on volume, and volume is where the record is thin. Five-year sales growth of about 12.75% against five-year profit growth of about 26.28% tells you plainly that most of the earnings compounding has come from margin expansion rather than from selling more.

Growth measure	Five-year record	What it implies
Sales CAGR	12.75%	Volume and price growth have been moderate
Profit CAGR	26.28%	Roughly half the earnings growth came from margin
Operating margin	40.31%	Already high; limited room for further expansion
Five-year average ROCE	28.58%	Current 36.42% is above the historical norm

Margin expansion is a finite engine. A business at 40% operating margin cannot repeat the last five years by reaching 60%. From here, earnings growth has to come from more tonnes sold — new customers, new geographies or new dosage platforms — and that is a slower, more visible process. The base case below assumes it happens gradually; the bear case assumes it largely does not.

Return ratios and the balance sheet

Return on equity of 27.67% and return on capital employed of 36.42% are earned without leverage worth discussing, and there is no promoter pledge at the cut-off. For a company of this size, an unlevered balance sheet is a meaningful part of the risk assessment, because it removes the financing failure mode entirely and leaves only the operating one.

Quality measure	6 August 2026 value	Reading
Return on equity	27.67%	High, and not manufactured with debt
Return on capital employed	36.42%	Above the 28.58% five-year average
Operating margin	40.31%	Franchise-grade for a small formulator
Five-year sales CAGR	12.75%	The constraint on the story
Five-year profit CAGR	26.28%	Margin-assisted rather than volume-driven
Promoter pledge	0%	No pledged holding at the cut-off

Valuation at the fixed price

At ₹250.05 the shares traded near 20.4 times trailing earnings and about 5.0 times book. The 52-week range ran from ₹130.60 to ₹257.15, so the cut-off price sat under 3% below the high after roughly doubling off the low.

Valuation metric	6 August 2026 value	Basis
Share price	₹250.05	Exchange close on the cut-off date
Reconciled market capitalisation	₹784 Cr	Price times about 3.1371 crore shares
Recalculated P/E	20.38×	₹250.05 divided by trailing EPS of ₹12.27
Recalculated price to book	5.01×	₹250.05 divided by ₹49.90 book value per share
Recalculated PEG	About 0.78	P/E divided by the 26.28% five-year profit CAGR
Dividend yield	About 0.50%	On the declared ₹1.25 final dividend
52-week range	₹130.60 – ₹257.15	Cut-off price under 3% below the high

Twenty times earnings for a 36% ROCE business with no debt is not an aggressive multiple in isolation. The reservation is the entry point rather than the price: buying a small, thinly traded company within 3% of its high leaves no margin for a disappointing quarter, and this is a company whose quarters are lumpy.

The source valuation fields did not reconcile to the price we fixed, so market capitalisation, P/E, price to book, PEG and yield were recomputed against the same ₹250.05 close and roughly 3.1371 crore shares. As a cross-check, trailing EPS of ₹12.27 on that share count implies about ₹38.5 crore of profit, which matches the reported FY26 outcome.

Liquidity is a genuine constraint here

The shares list only on the BSE and the company is worth under ₹1,000 crore. Both facts are ordinary for a business at this stage and both change how a position should be sized. Daily traded value is small enough that a modest order can move the price, exit during a market decline may be slow, and no institution is likely to provide a floor of research coverage or a bid. This is not a statement about business quality; it is a statement about the cost of changing your mind.

Valuation framework: paying for margin, waiting for volume

The scenario model compounds trailing EPS of ₹12.27 from the cut-off. It applies 147/365 of a year of growth to the 2026 row and one further full year to each subsequent row, then applies an exit price-to-earnings multiple. Figures are rounded to the nearest ₹5 and exclude dividends.

Scenario	Annual EPS growth	Exit P/E	Operating interpretation
Bear	10%	15×	Volume growth stays in low double digits and the margin cannot rise further
Base	16%	20×	New customers and export dossiers lift volume while margin holds near 40%
Bull	22%	26×	DRCOAT blends win share from established suppliers and the multiple re-rates

The bear case here is not a distressed outcome. It describes a company that keeps earning 36% on capital and simply grows at the rate it has averaged, which for a shareholder buying near the high is a mediocre return rather than a loss.

Vikram Thermo share price target 2026 to 2030

The grid above resolves those three assumption sets into yearly values. It is arithmetic on a stated base, not a prediction endorsed by the company, and it is sensitive to the exit multiple in exactly the way any small-cap scenario table is.

What would change the thesis

The case strengthens if quarterly revenue growth moves durably into the high teens, if export or regulated-market dossiers begin naming DRCOAT in volume, or if the ready-to-use blend mix keeps rising as a share of sales. Steady dividends and a continued absence of debt would support the quality argument.

It weakens if revenue growth stays near 5% while the multiple stays near 20 times, if a large global excipient supplier prices aggressively in India, if customer concentration proves higher than expected, or if the strong March quarter turns out to have pulled sales forward rather than added them.

Quarterly monitoring scorecard

Question	Constructive evidence	Warning sign
Is volume finally growing?	Revenue growth sustained above 15%	Another year near 5%
Is the margin defensible?	Operating margin holds near 40%	Sustained compression below 33%
Is the mix improving?	Ready-to-use blends outgrow base polymer	Revenue skews back to commodity grades
Is the customer base widening?	New dossiers and export approvals disclosed	Growth depends on one or two formulators
Is capital still productive?	ROCE stays above the 28.58% five-year mean	Capex rises without matching revenue
Is the quarter representative?	Growth repeats across consecutive quarters	One outsized quarter carries the year

What to weigh at the current price

The business is better than its size suggests: a specified, regulatorily sticky ingredient sold at a 40% operating margin with no debt and no pledge. The valuation, at roughly 20 times earnings, is fair rather than cheap for that quality. The unresolved issue is growth — five years of 12.75% sales compounding does not obviously justify buying within 3% of a 52-week high, and the margin lever that produced most of the past earnings growth is largely spent.

Our view is that this is worth owning for the franchise and the balance sheet, sized small, with the recognition that the volume evidence has not yet arrived. The next two revenue lines matter more than any margin commentary.

FAQ

What is the Vikram Thermo share price target for 2030?

The grid above gives bear, base and bull values derived from trailing EPS, a growth assumption and an exit multiple. The width of that range reflects genuine uncertainty about volume growth rather than false precision.

What does Vikram Thermo actually make?

Methacrylic-acid based polymers sold as DRUGCOAT, and ready-to-use coating blends sold as DRCOAT. They are applied to tablets and capsules to control where and how quickly the drug is released.

Why is the operating margin above 40%?

Because the product is a specified functional ingredient named in customers’ regulatory filings rather than a commodity. Switching suppliers can require re-filing, which supports pricing far better than volume alone would.

What is the biggest risk in Vikram Thermo shares?

Slow revenue growth against a full valuation. The company has compounded profit mainly by expanding margin, and at over 40% that lever is close to exhausted. The BSE-only listing and small size add liquidity risk on top.

Does Vikram Thermo pay a dividend?

Yes. The board declared a final dividend of ₹1.25 per share on ₹10 face value for FY26, which is roughly a 0.5% yield at the cut-off price.

When does Vikram Thermo report its next result?

Check the results calendar and confirm the board-meeting date from the company’s own BSE filing before relying on any estimate.

Related research

• Blue Jet Healthcare share price target
• Vinati Organics share price target
• Navin Fluorine share price target

Sources and methodology

• Vikram Thermo (India) on Screener
• Vikram Thermo FY26 results coverage
• Vikram Thermo Q3 FY26 result analysis
• Vikram Thermo supplier profile

Return and margin metrics are Screener figures captured on 6 August 2026, and the market price with its 52-week range comes from exchange closing data for that same session. Per-share ratios were recomputed against that single price. FY26 and Q4 FY26 figures are as reported in the company’s results disclosure and contemporaneous coverage, quoted in approximate terms where the underlying report was itself rounded. The live quote does not regenerate the fixed scenario grid.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. Price targets are scenario arithmetic, not promises. Verify current filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.